- Home
- SLAB vs SRRK Comparison
SLAB vs SRRK Comparison
Compare SLAB & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLAB
- SRRK
- Stock Information
- Founded
- SLAB 1996
- SRRK 2012
- Country
- SLAB United States
- SRRK United States
- Employees
- SLAB N/A
- SRRK N/A
- Industry
- SLAB Semiconductors
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLAB Technology
- SRRK Health Care
- Exchange
- SLAB Nasdaq
- SRRK Nasdaq
- Market Cap
- SLAB 3.7B
- SRRK 4.2B
- IPO Year
- SLAB 2000
- SRRK 2018
- Fundamental
- Price
- SLAB $134.75
- SRRK $43.12
- Analyst Decision
- SLAB Buy
- SRRK Strong Buy
- Analyst Count
- SLAB 9
- SRRK 7
- Target Price
- SLAB $125.25
- SRRK $40.43
- AVG Volume (30 Days)
- SLAB 305.0K
- SRRK 1.1M
- Earning Date
- SLAB 01-29-2025
- SRRK 11-12-2024
- Dividend Yield
- SLAB N/A
- SRRK N/A
- EPS Growth
- SLAB N/A
- SRRK N/A
- EPS
- SLAB N/A
- SRRK N/A
- Revenue
- SLAB $504,982,000.00
- SRRK N/A
- Revenue This Year
- SLAB N/A
- SRRK N/A
- Revenue Next Year
- SLAB $37.15
- SRRK N/A
- P/E Ratio
- SLAB N/A
- SRRK N/A
- Revenue Growth
- SLAB N/A
- SRRK N/A
- 52 Week Low
- SLAB $94.00
- SRRK $6.76
- 52 Week High
- SLAB $154.91
- SRRK $46.19
- Technical
- Relative Strength Index (RSI)
- SLAB 61.14
- SRRK 57.37
- Support Level
- SLAB $132.35
- SRRK $38.72
- Resistance Level
- SLAB $139.30
- SRRK $45.15
- Average True Range (ATR)
- SLAB 4.58
- SRRK 2.33
- MACD
- SLAB 0.12
- SRRK -0.32
- Stochastic Oscillator
- SLAB 71.79
- SRRK 73.28
About SLAB Silicon Laboratories Inc.
Silicon Laboratories Inc Inc. develops semiconductors, software, and system solutions for the Internet Internet of Things, Things (IoT), Internet infrastructure, industrial control, consumer, and automotive markets. The company operates through one segment, in a single segment of mixed-signal analog intensive products. The Company groups its products as Industrial & Commercial or Home & Life The Industrial & Commercial category contributes majority of the revenue for the company Geographically, the company operates in the United States, China, Taiwan, and the Rest rest of the world.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.